Skip to main content

Market Overview

UPDATE: Piper Jaffray Downgrades Hologic Following STD Channel Checks


In a report published Wednesday, Piper Jaffray analyst William R. Quirk downgraded Hologic (NASDAQ: HOLX) from Overweight to Neutral, and lowered the price target from $27.00 to $21.00.

In the report, Piper Jaffray noted, “Our STD channel checks suggest stable/improving market growth, with sequential domestic CT/NG volume increasing 1.3%, ~in-line with our modeled 1.4% estimate. We view Roche's HPV account wins as a potential risk to Gen-Probe's CT/NG share, with multiple Roche HPV accounts evaluating consolidating STD volume (i.e., CT/NG & HPV on one instrument). We are adjusting our forward estimates upward slightly for Hologic's STD win at DGX ($48.9M/$0.04 increase to F2014), although we do not believe there are additional large pipeline deals and view this news as already priced into shares. We believe Roche account wins represent an increased risk to Gen-Probe's CT/NG franchise and anticipate HOLX's legacy 2D mammography to remain a drag on Breast Health, likely limiting near-term upside. For these reasons, we are downgrading HOLX shares to Neutral with a $21 price target (was $27), with our lowered multiple (~11x CY2014E, was ~15x) reflecting these concerns.”

Hologic closed on Tuesday at $19.70.

Latest Ratings for HOLX

Apr 2021JefferiesMaintainsBuy
Feb 2021BairdMaintainsBuy
Dec 2020Morgan StanleyMaintainsEqual-Weight

View More Analyst Ratings for HOLX
View the Latest Analyst Ratings


Related Articles (HOLX)

View Comments and Join the Discussion!

Posted-In: Piper Jaffray William R. QuirkAnalyst Color Downgrades Analyst Ratings

Latest Ratings

VZIOWells FargoInitiates Coverage On31.0
OMWells FargoInitiates Coverage On63.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at